Novartis AG (NOVN) - Total Liabilities

Latest as of March 2026: CHF79.84 Billion CHF ≈ $100.94 Billion USD

Based on the latest financial reports, Novartis AG (NOVN) has total liabilities worth CHF79.84 Billion CHF (≈ $100.94 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Novartis AG to track the company's year-over-year net asset growth rate.

Novartis AG - Total Liabilities Trend (1998–2025)

This chart illustrates how Novartis AG's total liabilities have evolved over time, based on quarterly financial data. See Novartis AG free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Novartis AG Competitors by Total Liabilities

The table below lists competitors of Novartis AG ranked by their total liabilities.

Company	Country	Total Liabilities
Toyota Motor Corporation MX:TMN	Mexico	MX$64.50 Trillion
Nestlé S.A F:NESM	Germany	€101.08 Billion
Arm Holdings plc American Depositary Shares NASDAQ:ARM	USA	$2.42 Billion
BHP Group Ltd AU:BHP	Australia	AU$60.59 Billion
American Express Company NYSE:AXP	USA	$274.90 Billion
Thermo Fisher Scientific Inc NYSE:TMO	USA	$52.00 Billion
Citigroup Inc. NYSE:C	USA	$2.57 Trillion
Nestle S.A. SW:NESN	Switzerland	CHF94.09 Billion

Liability Composition Analysis (1998–2025)

This chart breaks down Novartis AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Novartis AG.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.85	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	2.07	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.67	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novartis AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novartis AG (1998–2025)

The table below shows the annual total liabilities of Novartis AG from 1998 to 2025.

Year	Total Liabilities	Change
2025-12-31	CHF68.97 Billion ≈ $87.20 Billion	+18.68%
2024-12-31	CHF58.12 Billion ≈ $73.48 Billion	+9.26%
2023-12-31	CHF53.20 Billion ≈ $67.25 Billion	-8.33%
2022-12-31	CHF58.03 Billion ≈ $73.37 Billion	-9.29%
2021-12-31	CHF63.97 Billion ≈ $80.88 Billion	-10.04%
2020-12-31	CHF71.11 Billion ≈ $89.90 Billion	+13.20%
2019-12-31	CHF62.82 Billion ≈ $79.42 Billion	-6.06%
2018-12-31	CHF66.87 Billion ≈ $84.54 Billion	+13.63%
2017-12-31	CHF58.85 Billion ≈ $74.40 Billion	+6.55%
2016-12-31	CHF55.23 Billion ≈ $69.83 Billion	+1.47%
2015-12-31	CHF54.43 Billion ≈ $68.82 Billion	-0.20%
2014-12-31	CHF54.54 Billion ≈ $68.96 Billion	+5.33%
2013-12-31	CHF51.78 Billion ≈ $65.47 Billion	-5.73%
2012-12-31	CHF54.93 Billion ≈ $69.44 Billion	+6.54%
2011-12-31	CHF51.56 Billion ≈ $65.18 Billion	-3.72%
2010-12-31	CHF53.55 Billion ≈ $67.70 Billion	+40.76%
2009-12-31	CHF38.04 Billion ≈ $48.10 Billion	+36.54%
2008-12-31	CHF27.86 Billion ≈ $35.23 Billion	+6.93%
2007-12-31	CHF26.06 Billion ≈ $32.94 Billion	-2.46%
2006-12-31	CHF26.71 Billion ≈ $33.77 Billion	+8.73%
2005-12-31	CHF24.57 Billion ≈ $31.06 Billion	+16.03%
2004-12-31	CHF21.17 Billion ≈ $26.77 Billion	+12.63%
2003-12-31	CHF18.80 Billion ≈ $23.77 Billion	+12.63%
2002-12-31	CHF16.69 Billion ≈ $21.10 Billion	+13.18%
2001-12-31	CHF14.75 Billion ≈ $18.64 Billion	+11.97%
2000-12-31	CHF13.17 Billion ≈ $16.65 Billion	-25.33%
1999-12-31	CHF17.64 Billion ≈ $22.30 Billion	-1.49%
1998-12-31	CHF17.90 Billion ≈ $22.63 Billion	--

About Novartis AG

SW:NOVN Switzerland Drug Manufacturers - General

Market Cap

$307.96 Billion

CHF243.59 Billion CHF

Market Cap Rank

#86 Global

#3 in Switzerland

Share Price

CHF127.66

Change (1 day)

+1.85%

52-Week Range

CHF92.37 - CHF130.50

All Time High

CHF130.50